Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isobromindione
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Isobromindione is a small molecule drug belonging to the class of indanediones, which are organic compounds containing an indane ring with two ketone groups. It has been used as a uricosuric agent, primarily for the treatment of gout by increasing uric acid excretion[2][4][6]. Its mechanism of action involves promoting renal excretion of uric acid, thereby lowering serum urate levels and reducing gout symptoms. The drug has reached at least clinical trial phase II but does not appear to be widely marketed or currently in use[6].
- Brand names
- Uridion
- Other names
- isobromindionaisobromindionumIsobromindione [INN]
02
Targets
URAT1 (Uric Acid Transporter 1)
Beyond the preview
Go deeper on isobromindione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isobromindione.